肝硬化并发多器官功能障碍的发病机制与治疗方案

顾天翊; 陆伦根

doi:10.3969/j.issn.1001-5256.2017.06.032

肝硬化并发多器官功能障碍的发病机制与治疗方案

DOI: 10.3969/j.issn.1001-5256.2017.06.032

上海交通大学附属第一人民医院消化科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2136
- HTML全文浏览量: 38
- PDF下载量: 445
- 被引次数: 0
出版历程
- 收稿日期: 2016-12-26
- 出版日期: 2017-06-20

Research advances in the pathogenesis of multiple organ dysfunction syndrome in patients with liver cirrhosis and related treatment regimens

Department of Gastroenterology, The First People's Hospital Affiliated to Shanghai Jiao Tong University

摘要

摘要: 近年研究表明,肝硬化门静脉高压引起的并发症常累及多个脏器,有学者称之为多器官功能障碍综合征。多器官发生衰竭时,患者短期死亡率明显上升,且死亡率与受累器官数目有关。简述了门静脉高压及内脏血管扩张的病理生理机制,总结了包括心、肺、肾、脑、肝等重要脏器的病理变化及发病机制。肝移植是目前最常用且最有效的治疗手段,但仍存在不足。认为需要进一步研究疾病发展过程中各环节的作用机制,未来可以发现更多靶点来预防及治疗肝硬化患者多器官功能障碍。
- 肝硬化 /
- 高血压,门静脉 /
- 多器官功能衰竭 /
- 综述
Abstract: Recent studies have shown that complications of cirrhotic portal hypertension often involve multiple organs, which is called multiple organ dysfunction syndrome by some scholars. When multiple organ failure occurs, there is a significant increase in patients' short-term death rate, and death rate is associated with the number of organs involved. This article briefly describes the physiopathologic mechanisms of portal hypertension and visceral vasodilation and summarizes the pathological changes of vital organs including the heart, lung, kidney, brain, and liver and related pathogenesis. At present, liver transplantation remains the most effective therapy, but it still has some shortcomings. It is pointed out that further studies are needed to investigate the mechanisms of action of each link in disease development, and more targets are needed in the future to prevent and treat multiple organ dysfunction syndrome in patients with liver cirrhosis.
- liver cirrhosis /
- hypertension, portal /
- multiple organ failure /
- review

HTML全文

参考文献(41)

[1]GARCIA-TSAO G, BOSCH J.Management of varices and variceal hemorrhage in cirrhosis[J].N Engl J Med, 2010, 362 (9) :823-832.

[2]MEHTA G, GUSTOT T, MOOKERJEE RP, et al.Inflammation and portal hypertension-the undiscovered country[J].J Hepatol, 2014, 61 (1) :155-163.

[3]SCHWABE RF, SEKI E, BRENNER DA.Toll-like receptor signaling in the liver[J].Gastroenterol, 2006, 130 (6) :1886-1900.

[4]TAURA K, de MINICIS S, SEKI E, et al.Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis[J].Gastroenterol, 2008, 135 (5) :1729-1738.

[5]STEIB CJ, HARTMANN AC, v HESLER C, et al.Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis[J].Lab Invest, 2010, 90 (7) :1024-1032.

[6]YOKOMORI H, ODA M, YOSHIMURA K, et al.Overexpression of apelin receptor (APJ/AGTRL1) on hepatic stellate cells and sinusoidal angiogenesis in human cirrhotic liver[J].J Gastroenterol, 2011, 46 (2) :222-231.

[7]MEJIAS M, COCH L, BERZIGOTTI A, et al.Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats[J].Gut, 2015, 64 (4) :657-666.

[8]HU LS, GEORGE J, WANG JH, et al.Current concepts on the role of nitric oxide in portal hypertension[J].World J Gastroenterol, 2013, 19 (11) :1707-1717.

[9]IWAKIRI Y, GROSZMANN RJ.Vascular endothelial dysfunction in cirrhosis[J].J Hepatol, 2007, 46 (5) :927-934.

[10]NISHIYAMA SK, ZHAO J, WRAY DW, et al.Vascular function and endothelin-1:tipping the balance between vasodilation and vasoconstriction[J].J Appl Phys, 2017, 122 (2) :354-360.

[11]SIRAGUSA M, FLEMING I.The e NOS signalosome and its link to endothelial dysfunction[J].Pflugers Arch, 2016, 468 (7) :1125-1137.

[12]DU PLESSIS J, VANHEEL H, JANSSEN CE, et al.Activated intestinal macrophages in patients with cirrhosis release NO and IL-6that may disrupt intestinal barrier function[J].J Hepatol, 2013, 58 (6) :1125-1132.

[13]BOLOGNESI M, di PASCOLI M, VERARDO A, et al.Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis[J].World J Gastroenterol, 2014, 20 (10) :2555-2563.

[14]MLLER S, HOBOLTH L, WINKLER C, et al.Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis[J].Gut, 2011, 60 (9) :1254-1259.

[15]MLLER S, HENRIKSEN JH, BENDTSEN F.Extrahepatic complications to cirrhosis and portal hypertension:haemodynamic and homeostatic aspects[J].World J Gastroenterol, 2014, 20 (42) :15499-15517.

[16]MLLER S, BERNARDI M.Interactions of the heart and the liver[J].Eur Heart J, 2013, 34 (36) :2804-2811.

[17]MONTECUCCO F, di MARZO V.At the heart of the matter:the endocannabinoid system in cardiovascular function and dysfunction[J].Trends Pharmacol Sci, 2012, 33 (6) :331-340.

[18]GASKARI SA, LIU H, MOEZI L, et al.Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats[J].Br J Pharmacol, 2005, 146 (3) :315-323.

[19]AL KURY LT, VOITYCHUK OI, ALI RM, et al.Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes[J].Cell Calcium, 2014, 55 (2) :104-118.

[20]ADEBAYO D, MORABITO V, DAVENPORT A, et al.Renal dysfunction in cirrhosis is not just a vasomotor nephropathy[J].Kidney Int, 2015, 87 (3) :509-515.

[21]KRAG A, BENDTSEN F, HENRIKSEN JH, et al.Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J].Gut, 2010, 59 (1) :105-110.

[22]DURAND F, GRAUPERA I, GINS P, et al.Pathogenesis of hepatorenal syndrome:implications for therapy[J].Am J Kidney Dis, 2016, 67 (2) :318-328.

[23]CAVALLIN M, KAMATH PS, MERLI M, et al.Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:a randomized trial[J].Hepatology, 2015, 62 (2) :567-574.

[24]MLLER S, BENDTSEN F.Cirrhotic multiorgan syndrome[J].Dig Dis Sci, 2015, 60 (11) :3209-3225.

[25]KOCH DG, FALLON MB.Hepatopulmonary syndrome[J].Clin Liver Dis, 2014, 18 (2) :407-420.

[26]KOCH DG, BOGATKEVICH G, RAMSHESH V, et al.Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans[J].Dig Dis Sci, 2012, 57 (2) :516-523.

[27]MACHICAO VI, FALLON MB.Hepatopulmonary syndrome[J].Semin Respir Care Med, 2012, 33 (1) :11-16.

[28]ZHANG J, YANG W, HU B, et al.Endothelin-1 activation of the endothelin B receptor modulates pulmonary endothelial CX3CL1 and contributes to pulmonary angiogenesis in experimental hepatopulmonary syndrome[J].Am Pathol, 2014, 184 (6) :1706-1714.

[29]RAEVENS S, GEERTS A, van STEENKISTE C, et al.Hepatopulmonary syndrome and portopulmonary hypertension:recent knowledge in pathogenesis and overview of clinical assessment[J].Liver Int, 2015, 35 (6) :1646-1660.

[30]IVERSEN P, SRENSEN M, BAK LK, et al.Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy[J].Gastroenterol, 2009, 136 (3) :863-871.

[31]DAM G, KEIDING S, MUNK OL, et al.Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake[J].Hepatology, 2013, 57 (1) :258-265.

[32]MOREAU R, JALAN R, GINES P, et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J].Gastroenterol, 2013, 144 (7) :1426-1437.

[33]ARROYO V, MOREAU R, JALAN R, et al.Acute-on-chronic liver failure:a new syndrome that will re-classify cirrhosis[J].J Hepatol, 2015, 62 (1) :131-143.

[34]SARIN SK, KEDARISETTY CK, ABBAS Z.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471.

[35]MOREAU R.The Pathogenesis of ACLF:The inflammatory response and immune function[J].Semin Liver Dis, 2016, 36 (2) :133-140.

[36]HERNAEZ R, SOLE, MOREAU R, et al.Acute-on-chronic liver failure:an update[J].Gut, 2017, 66 (3) :541-553.

[37]WASMUTH HE, KUNZ D, YAGMUR E, et al.Patients with acute on chronic liver failure display‘sepsis-like’immune paralysis[J].J Hepatol, 2005, 42 (2) :195-201.

[38]BERNSMEIER C, POP OT, SINGANAYAGAM A, et al.Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J].Gastroenterol, 2015, 148 (3) :603-615.

[39]LI H, CHEN HS, NYBERG SL.Extracorporeal liver support and liver transplant for patients with acute-on-chronic liver failure[J].Semin Liver Dis, 2016, 36 (2) :153-160.

[40]BAARES R, NEVENS F, LARSEN FS, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure:the RELIEF trial[J].Hepatology, 2013, 57 (3) :1153-1162.

[41]ZHENG Z, LI X, LI Z, et al.Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure:a meta-analysis and meta-regression[J].Exp Ther Med, 2013, 6 (4) :929-936.

施引文献

资源附件(0)

访问统计